摘要有一款口服GLP-1产品问世,礼来口服小分子GLP-1受体激动剂Orforglipron在两项关键III期试验中大获全胜,降糖效果显著优于SGLT-2抑制剂及安慰剂,且无饮食限制。关键临床突破2026年2月 —— 礼来公司(Eli Lilly)刚刚宣布,其备受瞩目的“口服版GLP-1”候选药物Orforglipron跨越了迄今为止最重要的临床障碍。这一被外界誉为**“药丸版司美格鲁肽(...
Source Link摘要有一款口服GLP-1产品问世,礼来口服小分子GLP-1受体激动剂Orforglipron在两项关键III期试验中大获全胜,降糖效果显著优于SGLT-2抑制剂及安慰剂,且无饮食限制。关键临床突破2026年2月 —— 礼来公司(Eli Lilly)刚刚宣布,其备受瞩目的“口服版GLP-1”候选药物Orforglipron跨越了迄今为止最重要的临床障碍。这一被外界誉为**“药丸版司美格鲁肽(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.